(90) evaluated the difference in tumor-infiltrating immune cells at baseline and during treatment at the single-cell level (10x Genomics) in two metastatic TNBC patients treated with the combination of nab-paclitaxel and pembrolizumab; the enrichment of IFN+ and GZMB+ CD8+ T cells was well as TRMs was found in responders at baseline, whereas significant myeloid infiltrates accompanied by the absence of PD-1-high T cells at baseline were features of nonresponders, thereby indicating the potential prognostic value of these cell subsets as predictors for immunochemotherapy. This evidence concerns the gene PDCD1 and neoplasm.